Maarten E A Reith, Bruce E Blough, Weimin C Hong, Kymry T Jones, Kyle C Schmitt, Michael H Baumann, John S Partilla, Richard B Rothman, Jonathan L Katz
BACKGROUND: Treatment of stimulant-use disorders remains a formidable challenge, and the dopamine transporter (DAT) remains a potential target for antagonist or agonist-like substitution therapies. METHODS: This review focuses on DAT ligands, such as benztropine, GBR 12909, modafinil, and DAT substrates derived from phenethylamine or cathinone that have atypical DAT-inhibitor effects, either in vitro or in vivo. The compounds are described from a molecular mechanistic, behavioral, and medicinal-chemical perspective...
February 1, 2015: Drug and Alcohol Dependence